MINIRIN INJECTION 4 MCG/ML

RECHON LIFE SCIENCES AB - SWEDENFERRING GMBH (GERMANY)🇸🇬 Health Sciences Authority

Approval Date: May 24, 1990
Approval ID: cb06f87cc0d36143
Company: RECHON LIFE SCIENCES AB - SWEDENFERRING GMBH (GERMANY)
Type: Therapeutic

Approval Details

Approval Id: cb06f87cc0d36143
Drug Name: MINIRIN INJECTION 4 MCG/ML
Product Name: MINIRIN INJECTION 4 MCG/ML
Approval Number: SIN04482P
Approval Date: 1990-05-24
Registrant: FERRING PHARMACEUTICALS PRIVATE LIMITED
Licence Holder: FERRING PHARMACEUTICALS PRIVATE LIMITED
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: INJECTION
Dosage: DOSAGE AND METHOD OF ADMINISTRATION Dosage Central diabetes insipidus The injection may be used when the intranasal or oral administration is considered unsuitable. Individual dosage is determined after testing of the effect on urine osmolality and diuresis at different dose levels. In the event of signs of water retention/hyponatraemia treatment should be interrupted and the dose should be adjusted. Normal dosage, intravenous injection: Adults: 1–4 mcg (0.25–1 ml) 1–2 times daily. Children above the age of 1 year: 0.4–1 mcg (0.1–0.25 ml) 1–2 times daily. Children below the age of 1 year: 0.2–0.4 mcg (0.05–0.1 ml) 1–2 times daily. For patients who have been controlled on intranasal MINIRIN and who must be switched to the injection form, either because of poor intranasal absorption, or because of the need for surgery, the comparable antidiuretic dose of the injection is about 10% of the intranasal dose. Renal concentrating capacity test Normal adult dose by intramuscular or subcutaneous injection is 4 mcg (1 ml) as a single dose. For children above the age of 1 year the dose is 1 to 2 mcg (0.25 to 0.5 ml) as a single dose. For children below the age of 1 year the dose is 0.4 mcg (0.1 ml) as a single dose. For children it is recommended to use primarily the intranasal presentation. After administration of MINIRIN injection, any urine collected within one hour is discarded. During the next 8 hours two portions of urine are collected for measurement of osmolality. Fluid restriction should be observed, see section Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. The reference level for normal urine osmolality after MINIRIN administration is 800 mOsm/kg for most patients. With values under this level, the test should be repeated. A repeated low result indicates an impaired ability to concentrate urine and the patient should be referred for further examination into the underlying cause of the malfunction. Haemophilia A and von Willebrand’s Disease MINIRIN injection is administered as an intravenous infusion at a dose of 0.3 mcg/kg bodyweight diluted in sterile physiological saline and infused slowly over 15–30 minutes. In adults and children weighing 10 kg or more, 50 ml of diluent is used; in children weighing 10 kg or less, 10 ml of diluent is used. If a positive effect is obtained, the initial MINIRIN dose may be repeated 1–2 times with intervals of 6–12 hours. Further repetition of the dose may result in a reduced effect. In patients with haemophilia the desired increase of VIII:C is appraised by the same criterion as in the treatment with factor VIII-concentrate. The VIII:C-concentration must be followed up regularly since in a few cases the effect has been seen to decrease with repeated doses. If the MINIRIN infusion does not lead to the desired increase of the VIII:C-concentration in plasma, the treatment may be complemented with a supply of factor VIII-concentrate. The treatment of patients with haemophilia should be conducted in consultation with each patient’s coagulation laboratory. Determination of the coagulation factor and bleeding time before MINIRIN-treatment: Plasma levels of VIII:C and vWF:Ag increase substantially after desmopressin administration. However, it has not been possible to establish any correlation between the plasma concentration of these factors and the bleeding time, either before or after desmopressin. The effect of desmopressin on the bleeding time should therefore, if possible, be tested in the individual patient. The bleeding time test should be as standardized as possible, e.g. with the use of Simplate II. Determination of bleeding time and plasma levels of the coagulation factors should be conducted in cooperation or consultation with a coagulation laboratory. Posology for special populations Renal impairment MINIRIN injection should be used with caution in patients with moderate and severe renal insufficiency (see section Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Hepatic impairment No studies have been performed in this population. It is unlikely that desmopressin will interact with drugs affecting hepatic metabolism, since desmopressin has been shown not to undergo significant liver metabolism in in vitro studies with human microsomes. Method of administration The injection is normally administered intravenously but may, if needed, also be given intramuscularly or subcutaneously, depending on the indications.
Route Of Administration: INTRAVENOUS, SUBCUTANEOUS, INTRAMUSCULAR
Indication Info: THERAPEUTIC INDICATIONS Central diabetes insipidus The use of MINIRIN in patients with an established diagnosis will result in a reduction in urinary output with concomitant increase in urine osmolality and decrease in plasma osmolality. This will result in decreased urinary frequency and decreased nocturia. Renal concentrating capacity test MINIRIN can be used to test the capacity of the kidneys to concentrate urine; as a diagnostic aid in the examination of the kidney function. This is especially useful in the differential diagnosis between level of urinary tract infections. Cystitis will opposite to pyelonephritis not cause a subnormal ability to concentrate urine. Hemophilia A and von Willebrand’s disease For the therapeutic control of bleeding and bleeding prophylaxis in connection with minor surgical procedures in patients with mild haemophilia A and von Willebrand’s disease who respond positively to the test dose. In exceptional cases, even moderate forms of the disease can be treated. MINIRIN must not be used in patients with von Willebrand’s disease type II B.
Contraindications: CONTRAINDICATIONS <ul class="dash"> <li>Hypersensitivity to the active substances or to any of the excipients</li> <li>Habitual or psychogenic polydipsia (resulting in a urine production exceeding 40 ml/kg/24 hours)</li> <li>A history of unstable angina and/or known or suspected cardiac insufficiency and other conditions requiring treatment with diuretics</li> <li>Known hyponatraemia</li> <li>Syndrome of inappropriate ADH secretion (SIADH)</li> <li>von Willebrand’s disease type IIB</li> </ul>
Atc Code: H01BA02
Atc Item Name: desmopressin
Pharma Manufacturer Name: FERRING PHARMACEUTICALS PRIVATE LIMITED
Company Detail Path: /organization/ferring-pharmaceuticals-private-limited

Active Ingredients

Desmopressin 3.56 mcg/ml eqv Desmopressin Acetate

4 mcg/ml

Desmopressin 3.56 mcg/ml eqv Desmopressin Acetate

4 mcg/ml

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

May 24, 1990

Approval ID

cb06f87cc0d36143

Type

Therapeutic

Back to HSA Approvals